semaglutide banned in mississippi pharmacists warned about compounding weight loss drugs Health - Axios

Novo Nordisk first synthesized semaglutide and brought it into clinical development, recognizing its potential as a longer-acting and more potent alternative to earlier GLP-1 analogs like liraglutide (Victoza)

According to Yu-Ming Ni, MD, a board-certified cardiologist and lipidologist at MemorialCare Heart and Vascular Institute at Orange Coast Medical Center in Fountain Valley, California, they promote weight loss, a significant factor in reducing cardiovascular risk

GLP-1s are distinct from previous classes of prescription weight loss drugs such as phentermine, as they target essential metabolic pathways

Patients who tend to see the largest improvements: High baseline triglycerides (200+ mg/dL)

Citrate-based formulas tend to sit better on sensitive stomachs